The online version of this article (doi:10.1186/1471-2296-15-3) contains supplementary material, which is available to authorized users.
All authors declare to have no competing interests.
AGF, KL and PBR participated in the conception and design of the study. AGF, CP and ES monitored data collection. AGF, KL, CP analysed and checked the data calculation. All authors participated in data interpretation, drafting, and revising the manuscript. All authors read and approved the final manuscript.
Primary care physicians are gate keepers to the medical system having a key role in giving information and prescribing drugs to their patients. In this respect they are involved in claims of patients/clients for pharmacological Cognitive Enhancement (CE). Therefore, we studied the knowledge of primary care physicians about CE and their attitudes toward prescribing CE drugs to healthy subjects.
A self-report paper-and-pencil questionnaire and case vignettes describing a hypothetical CE drug were sent out to all 2,753 registered primary care physicians in Rhineland Palatine, Germany. 832, i.e. 30.2% filled in the questionnaire anonymously.
96.0% of all participating physicians had already heard about CE. However, only 5.3% stated to be very familiar with this subject and 43.5% judged themselves as being not familiar with CE. 7.0% had been asked by their clients to prescribe a drug for CE during the last week, 19.0% during the last month, and 40.8% during the last year. The comfort level to prescribe CE drugs was very low and significantly lower than to prescribe sildenafil (Viagra®). Comfort level was mainly affected by the age of the client asking for prescription of CE drugs, followed by the availability of non-pharmacological alternatives, fear of misuse of the prescribed drug by the client and the missing indication of prescribing a drug.
Although a relatively high proportion of primary care physicians have been asked by their clients to prescribe CE drugs, only a small proportion are well informed about the possibilities of CE. Since physicians are gate keepers to the medical system and have a key role regarding a drugs’ prescription, objective information should be made available to physicians about biological, ethical and social consequences of CE use.
Laux G, Kühlein T, Gutscher A, Szecsenyi J: Versorgungsforschung in der Hausarztpraxis. Ergebnisse aus dem CONTENT-Projekt 2006–2009. 2010, Heidelberg: Springer-Verlag
Lieb K: Hirndoping - Warum wir nicht alles schlucken sollen. 2010, Artemis & Winkler: Düsseldorf
Franke AG, Lieb K: Pharmacological Neuroenhancement: Substances and Epidemiology. Cognitive Enhancement - An Interdisciplinary Perspective by Hildt E, Franke AG. 2013, Heidelberg: Springer Verlag, 17-27.
Schwabe U, Paffrath D: Arzneiverordnungs-Report 2010. 2010, Heidelberg: Springer-Verlag CrossRef
Banjo OC, Nadler R, Reiner PB: Physician attitudes towards pharmacological cognitive enhancement: safety concerns are paramount. PLoS One. 2011, 5 (12): e14322- CrossRef
Webb JR, Valasek MA, North CS: Prevalence of stimulant use in a sample of US medical students. Ann Clin Psychiatry. 2013, 25 (1): 27-32. PubMed
Middendorf E, Poskowsky J, Isserstedt W: Formen der Stresskompensation und Leistungssteigerung bei Studierenden. HISBUS-Befragung zur Verbreitung und zu Mustern von Hirndoping und Medikamentenmissbrauch. 2012, HIS Hochschul-Informations-System GmbH: Hannover
Ponnet K, Wouters E, Van Hal G, Heirman W, Walrave M: Determinants of physicians' prescribing behaviour of methylphenidate for cognitive enhancement. Psychol Health Med. 2013
- Attitudes towards prescribing cognitive enhancers among primary care physicians in Germany
Andreas G Franke
Peter B Reiner
- BioMed Central
Neu im Fachgebiet Allgemeinmedizin
Meistgelesene Bücher aus dem Fachgebiet
Mail Icon II